|
Interagency Coordinating Committee on Human Growth Hormone and Creutzfeldt - Jakob disease
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA
|
NIDDK, NICHD, NINDS
|
The Public Health Service Interagency Coordinating Committee on Human Growth Hormone (hGH) and Creutzfeldt-Jakob Disease (CJD) was established in 1985 by the Assistant Secretary for Health, the Department of Health and Human Services (HHS) to review information relevant to patients who received pituitary-derived hGH that was distributed through the NIH-funded National Hormone and Pituitary Program (NHPP). The Committee analyzes this information to determine the extent of the problem of transmission of CJD (a rare, incurable brain disease) through contaminated pituitary hGH, and to inform physicians and patients who received pituitary hGH about the health risks associated with pituitary hGH. Although NHPP’s distribution of hGH ceased when its potential to transmit CJD was discovered in 1985—and today, recombinant growth hormone that is not susceptible to CJD contamination is exclusively used for treatment—the Committee continues to maintain oversight of this issue because CJD may take years or decades to develop. The Committee includes representatives from the National Institutes of Health (NIH), the Food and Drug Administration (FDA), and the Centers for Disease Control and Prevention (CDC), and is chaired by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Director.
|
|
Interagency Coordinating Committee on the Prevention of Underage Drinking (ICCPUD)
|
Committee, Work group, Advisory group, or Task Force
|
ACF, CDC, IHS, OS, OSG, SAMHSA
|
NIDA, NIAAA
|
The Consolidated Appropriations Act of 2004 directed the Secretary of Health and Human Services (HHS) to establish the Interagency Coordinating Committee on the Prevention of Underage Drinking (ICCPUD) and to issue an annual report summarizing all Federal agency activities related to preventing underage alcohol use. HHS made ICCPUD a standing committee to provide ongoing, high-level leadership on this issue and to serve as a mechanism for coordinating Federal efforts aimed at preventing and reducing underage drinking. The Substance Abuse and Mental Health Services Administration (SAMHSA) serves as the lead ICCPUD agency.
|
|
Interagency Group for Development of Lung Infection Models for P. aeruginosa and A.baumannii
|
Committee, Work group, Advisory group, or Task Force
|
BARDA, CDC, FDA
|
NIAID
|
This interagency working group meets quarterly to discuss the development of various lung infection animal models.
|
|
Interagency Group on Alzheimer''s Disease and Related Dementias for implementation of the National Alzheimer''s Project Act
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, CMS, FDA, HRSA
|
NIA
|
This interagency group was established by Department of Health and Human Services(HHS) in response to the Congressional directive to address Alzheimer disease. Under the National Alzheimer’s Project Act, HHS created three sub-groups on Research, Long Term Services, and Clinical Services. The Veteran’s Administration, National Science Foundation, and Department of Defense are also involved in this effort.
|
|
Interagency Modeling and Analysis Group (IMAG)
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, FDA
|
NIBIB, CSR, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NLM, OD/DPCPSI, OD/DPCPSI/OBSSR
|
IMAG is comprised of program directors from over 10 government agencies including the National Institutes of Health (NIH), the National Science Foundation (NSF), Department of Energy (DOE), Department of Defense (DOD), the Department of Agriculture (USDA), the National Aeronautics and Space Administration (NASA), the Department of Veterans Administration (VA), the Food and Drug Administration (FDA), and the Intelligence Advanced Research Projects Activity (IARPA). The purpose of IMAG is to bring together program officers who have a shared interest in supporting modeling and analysis methods in biomedical, biological, and behavioral systems. IMAG has promoted and supported a wide variety of modeling, notably multi-scale modeling (MSM) through agency-specific funding opportunity announcements. IMAG also holds consortium meetings annually. . Following the Fall 2019 meeting, two papers were published because of discussions at that meeting:
• Review article published Feb. 18, 2020 in the Archives of Computational Methods in Engineering.
• Meeting perspective paper published Nov. 25, 1019 in NPJ Digital Medicine based on an Oct. 24, 2019 ML-MSM meeting.
The MSM held its 13th annual workshop virtually in March 2019 with the theme: Amplifying Impact by Nurturing Diversity.
|
|
Interagency Oncology Task Force Fellowship: Track 4
|
Training Initiative
|
FDA
|
NCI
|
This fellowship will provide training in cancer prevention (e.g., chemoprevention, vaccination, and early detection). Individuals will be trained in the drug, biologic, or device development and approval processes and their application to study populations (including healthy subjects) to facilitate the movement of novel approaches from the bench to the community. Combining training in public health, cancer prevention research, and research-related regulatory overview will allow individuals to develop expertise across these disciplines.
|
|
Interagency Pain Research Coordinating Committee (IPRCC)
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, FDA
|
NINDS, NCCIH, NIDA, NIDCR, NINR
|
The Interagency Pain Research Coordinating Committee is an Affordable Care Act-mandated committee to coordinate pain research activities across the government.
|
|
Interagency Select Agent Review Group (ISARG)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, OS
|
NIAID, OD/OM/OB, OD/OSP
|
The Interagency Select Agent Review Group (ISARG), composed of members from the Centers for Disease Control and Prevention (CDC), the Department of Justice, the Department of State, the National Institutes of Health Office of the Director (NIH-OD) and the Biomedical Advanced Research and Development Authority (BARDA), advises the National Institute of Allergy and Infectious Diseases (NIAID) on whether facilities and procedures at NIAID-funded foreign research sites are comparable to those required by the Select Agent Regulations for domestic institutions before Select Agent work at the foreign site may proceed.
|
|
Interagency Serological Working Group
|
Committee, Work group, Advisory group, or Task Force
|
BARDA, CDC, FDA
|
NIAID
|
Coordinating influenza serological studies and capabilities across agencies.
|
|
Interagency Task Force on Military and Veterans Mental Health (ITF)
|
Committee, Work group, Advisory group, or Task Force
|
ACL, OS, SAMHSA
|
NIMH
|
Executive Order 13625, Improving Access to Mental Health Services for Veterans, Service Members, and Military Families, was released on August 31, 2012, and directed the Department of Defense (DoD), Veterans Affairs (VA), and Health and Human Services (HHS) to ensure that Veterans, Service Members, and their families have access to needed mental health services and support. The Executive Order also established the Interagency Task Force on Military and Veterans Mental Health (ITF) and directed it to provide an annual review of agency actions, to define specific goals and metrics to aid in measuring progress, and make additional recommendations as appropriate to the President to improve mental health and substance use disorder treatment services for Veterans, Service Members, and their families. The ITF, co-chaired by the DoD Assistant Secretary for Health Affairs, the VA Under Secretary for Health, and the HHS Administrator for the Substance Abuse and Mental Health Services Administration, tracks and reports progress in executing all activities resulting from recommendations made pursuant to the Executive Order.
|